Every monsoon season, a silent epidemic sweeps through the paddy fields of Assam, Uttar Pradesh, and West Bengal. Children who were perfectly healthy in the morning are brought to hospitals in the evening with raging fevers, convulsions, and altered consciousness. Many will not recover. Those who do often carry permanent neurological damage — paralysis, speech loss, cognitive impairment — for the rest of their lives. The culprit is Japanese Encephalitis (JE), a mosquito-borne viral brain infection that remains one of the leading causes of viral encephalitis in Asia. India reported 1,548 confirmed JE cases in 2024 across 24 states, with Assam alone accounting for nearly half of them. A vaccine that is over 90% effective exists — yet awareness and vaccination coverage remain dangerously low.
What Is Japanese Encephalitis?
Japanese Encephalitis (JE) is caused by the Japanese Encephalitis Virus (JEV), a flavivirus transmitted to humans through the bite of infected Culex mosquitoes — particularly Culex tritaeniorhynchus, which breeds in the stagnant, nutrient-rich water of irrigated rice paddies and marshes. The virus is maintained in a transmission cycle between mosquitoes, pigs, and water birds (especially herons and egrets); humans are a dead-end host and do not spread the virus further.
JE is not contagious from person to person. You cannot get it from an infected family member or patient.
Despite its name, Japanese Encephalitis is most prevalent in South and Southeast Asia, not Japan — where decades of aggressive vaccination have reduced cases to near-zero. India is now one of the countries most severely affected.
How Common Is JE in India?
| Year | Reported JE Cases | Deaths | States Reporting |
|---|---|---|---|
| 2022 | 1,271 | ~130 | 24 |
| 2023 | 1,320 | ~140 | 24 |
| 2024 | 1,548 | ~160 | 24 |
JE is endemic in 355 districts across 24 States and Union Territories in India. The most severely affected states are Assam, Uttar Pradesh, West Bengal, Bihar, Andhra Pradesh, Telangana, Karnataka, Tamil Nadu, Odisha, and Manipur. Assam alone contributes 30–50% of India's total JE burden — with rice farming, wetlands, and pig rearing creating ideal conditions for transmission.
Who Is at Risk?
Most Vulnerable Groups
- Children aged 1–15 years in endemic areas are the most at-risk group — both because they are less likely to have received the vaccine and because their immune systems are still developing. Over 70% of JE cases in India occur in children.
- Rural agricultural communities — particularly those who work in or near rice paddies, live close to water bodies, or keep pigs — face the highest exposure to infected mosquitoes.
- Travellers to endemic areas during the monsoon and post-monsoon season (July–November) without prior vaccination.
- Unvaccinated adults in newly endemic areas — JE is spreading to non-traditional districts as changing rainfall patterns and irrigation expansion create new mosquito habitats.
When Is JE Season?
JE in India peaks sharply during and after the monsoon:
- July to October: Core high-transmission season across most endemic states.
- October to December: Extended season in Tamil Nadu and Andhra Pradesh (second rice crop season).
- Year-round, low risk: In states like Kerala and Karnataka where irrigation is continuous.
Understanding JE: How the Virus Attacks the Brain
Of every 250–300 people infected with JEV, the vast majority (over 99%) either have no symptoms at all or develop only a mild, self-limiting fever. However, in roughly 1 in 250 infections, the virus crosses the blood-brain barrier and causes encephalitis (inflammation of the brain) — and this is where JE becomes devastating.
Once encephalitis develops:
- Case fatality rate is 20–30% — one in four or five patients with JE encephalitis dies, despite best supportive care.
- 30–50% of survivors are left with permanent neurological disabilities — paralysis, seizure disorders, speech and cognitive impairment, behavioural changes, and intellectual disability.
- Only 20–30% of JE encephalitis patients recover completely.
This makes JE one of the most feared neurological infections in India, even though individual infection risk is relatively low — because the consequences when it does progress are so severe.
Symptoms of Japanese Encephalitis
JE goes through three recognisable phases:
Phase 1: Prodromal Stage (Days 1–3)
Initial symptoms are non-specific and easily mistaken for dengue, typhoid, or viral fever:
- Sudden high fever (38–40°C)
- Severe headache
- Nausea and vomiting
- Fatigue and body ache
- Loss of appetite
At this stage, the fever is indistinguishable from many other infections. This is why JE is often missed on the first visit to a doctor.
Phase 2: Acute Encephalitic Stage (Days 3–7)
As the virus invades brain tissue, neurological signs emerge rapidly:
- Altered consciousness: Confusion, disorientation, and difficulty recognising family members.
- Seizures: Especially in children — often the first dramatic sign that brings families to the hospital.
- Stiff neck and photophobia: Meningeal irritation.
- Movement abnormalities: Abnormal jerking (extrapyramidal signs), rigidity, or unusual limb posturing.
- Coma: In severe cases, patients may deteriorate into deep unconsciousness within 24–48 hours.
A child who develops high fever followed rapidly by seizures or confusion during the monsoon season in an endemic area should be treated as a medical emergency.
Phase 3: Late Stage and Outcome
For those who survive the acute phase, recovery is a long road. Neurological deficits may persist for months or be permanent. Common long-term complications include:
- Epilepsy (recurring seizures)
- Motor deficits — weakness, spasticity, or paralysis of limbs
- Cognitive impairment and poor school performance
- Speech and language difficulties
- Psychiatric or behavioural changes
Rehabilitation, including physiotherapy, speech therapy, and special education support, is critical for affected children and is available at tertiary government hospitals in most endemic states.
Diagnosis of Japanese Encephalitis
When to Suspect JE
A doctor will suspect JE in any patient — especially a child — presenting with:
- Fever + neurological signs (seizures, confusion, altered consciousness)
- Residence in or travel to a JE-endemic area
- Monsoon or post-monsoon timing
- No other clear cause of encephalitis after ruling out bacterial meningitis
Diagnostic Tests
| Test | What It Detects | Notes |
|---|---|---|
| IgM antibody capture ELISA (MAC-ELISA) | JE-specific IgM antibodies in blood or CSF | Gold standard; results in 1–2 days; widely available at NCDC and state labs |
| CSF analysis (Lumbar Puncture) | White cell count, protein, glucose | Confirms encephalitis; CSF IgM is more specific than blood IgM |
| MRI Brain | Bilateral thalamic lesions (classic JE pattern) | Highly suggestive when present; not always available |
| CT Scan Brain | Thalamic or basal ganglia involvement | Less sensitive than MRI for early JE |
| Plaque Reduction Neutralisation Test (PRNT) | Confirmatory antibody test | Reference labs only; used to distinguish from dengue cross-reactivity |
| RT-PCR (Viral RNA) | JEV RNA in blood/CSF | Useful only in early viraemia; often negative by encephalitis stage |
The MAC-ELISA for JE-specific IgM in cerebrospinal fluid (CSF) is the test used by India's national surveillance programme and provides results in 24–48 hours. Blood IgM can produce false positives in dengue-endemic areas due to antibody cross-reactivity.
All JE testing in suspected encephalitis cases is available free of charge at government medical college hospitals and ICMR/NCDC-designated sentinel surveillance sites across endemic states. If your child is hospitalised with fever and seizures during monsoon season in an endemic state, your doctor should order JE serology as part of the workup.
After discharge, keeping a complete, organised record of all brain imaging, lab results, and follow-up consultations is crucial for long-term care. Upload your medical reports to MedicalVault and use the family sharing feature to ensure neurologists and rehabilitation specialists all have access to the same complete history — especially important for children who may see multiple specialists over years.
Treatment of Japanese Encephalitis
There is currently no specific antiviral drug approved for JE. Treatment is entirely supportive and aimed at managing complications:
Supportive Care in Hospital
- Fever management: Paracetamol; careful use of NSAIDs.
- Seizure control: Intravenous phenobarbital, phenytoin, or levetiracetam for acute seizure management.
- Raised intracranial pressure: IV mannitol or hypertonic saline; elevating the head of the bed.
- Airway protection: Mechanical ventilation if consciousness deteriorates significantly.
- Hydration and nutrition: IV fluids, nasogastric feeding if swallowing is impaired.
- Prevention of secondary infections: Aspiration pneumonia, urinary tract infections, and pressure sores are common in comatose patients.
Patients with JE encephalitis should be managed in a hospital with neurological ICU capabilities. In India, government medical colleges and district hospitals in endemic areas have designated JE wards during peak season — access these services promptly.
Research on Treatments
Several antiviral drugs (including minocycline and celecoxib) have been studied for JE, but none has demonstrated sufficient efficacy in clinical trials to be recommended. Research continues into immunomodulatory approaches. For now, prevention through vaccination remains the only proven intervention.
The JE Vaccine: Your Best Protection
Vaccination is the cornerstone of JE prevention — and two JE vaccines are used in India:
SA 14-14-2 Live Attenuated Vaccine
- Manufactured in China (Chengdu Institute of Biological Products); the most widely used JE vaccine globally.
- A single dose provides over 90% protection within 1–2 months.
- Two doses: first at 9–12 months, booster at 16–24 months (under India's National Immunisation Schedule).
- Used in India's UIP (Universal Immunisation Programme) for endemic districts.
JENVAC (Inactivated Vaccine — Made in India)
- Developed by Biological E. Limited, Hyderabad — India's first indigenous JE vaccine.
- Two doses (0.5 ml each) on days 0 and 28, intramuscular.
- Seroconversion rate >90% after two doses.
- Available for private purchase; also used in government programmes.
Who Should Be Vaccinated?
Under India's National Immunisation Programme (NIP):
- All children in JE-endemic districts receive the JE vaccine at 9–12 months (first dose) and 16–24 months (second dose) as part of the childhood immunisation schedule.
- Check with your nearest PHC or government hospital if your district is in the endemic list.
Outside the NIP (voluntary vaccination):
- Children aged 1–15 in endemic areas who have not received the vaccine
- Adults in endemic areas — particularly agricultural workers, healthcare workers, and those with high exposure
- Travellers to endemic areas during monsoon season (especially those staying in rural areas for ≥1 month)
- Pregnant women: JE vaccination is deferred during pregnancy; consult your doctor.
The JE vaccine costs approximately ₹400–₹800 per dose at private clinics in India. In government hospitals and health centres in endemic districts, the vaccine is provided free of charge.
Prevention Beyond Vaccination
Mosquito Protection
- Sleep under insecticide-treated mosquito nets (ITNs): The Culex tritaeniorhynchus mosquito feeds between dusk and dawn.
- Use repellents: Apply DEET-based repellents (Odomos) or pyrethroid-based coils and vaporisers, especially in the evening.
- Wear full-sleeved clothing after sunset in endemic areas during monsoon season.
- Screen windows and doors in the home.
Environmental Precautions
- Limit evening outdoor activity near paddy fields and water bodies during JE season.
- Avoid keeping pig sties close to homes — pigs are amplifying hosts and proximity sharply increases mosquito-to-human JEV transmission.
- Larviciding and fogging: Support local municipal and panchayat-level mosquito control efforts, especially before and during the monsoon.
Travel Advice
If you are travelling to rural endemic areas (particularly Assam, UP, or West Bengal) during July–November:
- Vaccinate with JENVAC at least 1 month before travel (two doses needed).
- Carry and consistently use mosquito repellent.
- Sleep with a mosquito net.
Tracking Neurological Recovery
For families managing a child or adult recovering from JE encephalitis, long-term record-keeping is critical. Progress in physiotherapy, neurology follow-ups, EEG reports, MRI scans, and cognitive assessments all need to be tracked over months and years. Use MedicalVault's trend analysis to monitor how neurological parameters change over time and ensure every specialist — neurosurgeon, physiotherapist, speech therapist, paediatrician — works from the same complete medical history.
Key Takeaways
- Japanese Encephalitis is a real and serious risk in India, endemic in 355 districts across 24 states; most cases occur in Assam, UP, West Bengal, Bihar, and Andhra Pradesh during the monsoon (July–November).
- Children under 15 are most at risk — 70% of Indian JE cases are in children; most live in rural agricultural communities.
- Over 99% of infections are mild or asymptomatic, but when encephalitis develops, the case fatality rate is 20–30% and 30–50% of survivors have permanent neurological disability.
- There is no antiviral cure — treatment is supportive. Prevention through vaccination is the only proven way to avoid JE.
- A highly effective vaccine exists — both SA14-14-2 and JENVAC offer >90% protection; the JE vaccine is free under India's National Immunisation Programme for children in endemic districts.
- Monsoon-season fever + seizures in a child from an endemic area = medical emergency — seek hospital care immediately.
- Organise all JE-related records — brain scans, lab results, rehabilitation reports — using MedicalVault's family sharing and trend tracking, essential for the long-term, multi-specialist care JE survivors require.
If you live in an endemic district, take your children for the JE vaccine today. If you have missed doses under the government schedule, contact your nearest PHC or district hospital — the vaccine is free, effective, and can prevent a lifetime of disability.